Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.
Structural modifications were made to a previously described acyl dipeptide caspase inhibitor, leading to the oxamyl dipeptide series. Subsequent SAR studies directed toward the warhead, P2, and P4 regions of this novel peptidomimetic are described herein.
Linton
Steven D
SD
Idun Pharmaceuticals, Inc., 9380 Judicial Drive, San Diego, CA 92121, USA. slinton@idun.com
Aja
Teresa
T
Allegrini
Peter R
PR
Deckwerth
Thomas L
TL
Diaz
Jose-Luis
JL
Hengerer
Bastian
B
Herrmann
Julia
J
Jahangiri
Kathy G
KG
Kallen
Joerg
J
Karanewsky
Donald S
DS
Meduna
Steven P
SP
Nalley
Kip
K
Robinson
Edward D
ED
Roggo
Silvio
S
Rovelli
Giorgio
G
Sauter
Andre
A
Sayers
Robert O
RO
Schmitz
Albert
A
Smidt
Robert
R
Ternansky
Robert J
RJ
Tomaselli
Kevin J
KJ
Ullman
Brett R
BR
Wiessner
Christoph
C
Wu
Joe C
JC
D017209:Apoptosis / Q000187:drug effects; D002219:Carbamates; D061945:Caspase Inhibitors; D002460:Cell Line; D004151:Dipeptides / Q000138:chemical synthesis* / Q000494:pharmacology*; D006801:Humans; D020128:Inhibitory Concentration 50; D007700:Kinetics; D019636:Neurodegenerative Diseases / Q000188:drug therapy; D020521:Stroke / Q000188:drug therapy; D013329:Structure-Activity Relationship
D002219:Carbamates; D061945:Caspase Inhibitors; D004151:Dipeptides; C011960:oxamyl